2017
Pathogenesis of hypothyroidism-induced NAFLD is driven by intra- and extrahepatic mechanisms
Ferrandino G, Kaspari RR, Spadaro O, Reyna-Neyra A, Perry RJ, Cardone R, Kibbey RG, Shulman GI, Dixit VD, Carrasco N. Pathogenesis of hypothyroidism-induced NAFLD is driven by intra- and extrahepatic mechanisms. Proceedings Of The National Academy Of Sciences Of The United States Of America 2017, 114: e9172-e9180. PMID: 29073114, PMCID: PMC5664516, DOI: 10.1073/pnas.1707797114.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseDe novo lipogenesisAdipose tissue lipolysisHepatic insulin resistanceThyroid hormonesHypothyroid miceImpaired suppressionInsulin resistanceTissue lipolysisInsulin secretionHigh thyroid-stimulating hormone levelsRegulation of THThyroid-stimulating hormone levelsLipid utilizationFatty liver diseaseSerum glucose levelsEndogenous glucose productionLow thyroid hormoneFatty acidsHepatic lipid utilizationLiver diseaseSevere hypothyroidismHormone levelsProfound suppressionGlucose levels
2015
Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats
Perry RJ, Zhang D, Zhang XM, Boyer JL, Shulman GI. Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats. Science 2015, 347: 1253-1256. PMID: 25721504, PMCID: PMC4495920, DOI: 10.1126/science.aaa0672.Peer-Reviewed Original ResearchMeSH Keywords2,4-DinitrophenolAnimalsBlood GlucoseDelayed-Action PreparationsDiabetes Mellitus, Type 2Glucose Tolerance TestInsulin ResistanceLipid MetabolismLiver CirrhosisMaleMiceMitochondria, LiverMuscle, SkeletalNon-alcoholic Fatty Liver DiseaseOxidation-ReductionProton IonophoresRandom AllocationRatsRats, ZuckerConceptsNonalcoholic fatty liver diseaseNonalcoholic steatohepatitisInsulin resistanceRat modelControlled-release oral formulationsPlasma transaminase concentrationsFatty liver diseaseType 2 diabetesMitochondrial uncouplingProtein-synthetic functionChronic treatmentLiver diseaseMetabolic syndromeTransaminase concentrationsHepatic steatosisLiver fibrosisEffective therapyPreclinical modelsOral formulationSystemic toxicityClinical useRelated epidemicsBeneficial effectsSynthetic functionMitochondrial protonophore
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply